Essa Pharma Inc. announced an ex-dividend date for a return of capital distribution of $80,000,000 to shareholders.
The distribution will be approximately $1.69 per common share and is part of the discontinuance and winding-up of the business due to a transaction with XenoTherapeutics, Inc.
Nasdaq declared an ex-dividend date of August 25, 2025, with trading in due bills from August 19 to August 25, 2025.
Distribution Details
$80,000,000 return of capital distribution with $1.69 per common share.
Trading Information
Common shares will trade with 'due bills' representing the right to the distribution during the Due Bill Period.
Shareholder Actions
Shareholders selling during the Due Bill Period forfeit their right to the distribution; buyers will receive the distribution.
Due Bill Obligations
Sellers during the Due Bill Period must deliver the distribution to buyers; obligations are settled between brokers.
Transaction with Xeno
Transaction involves XenoTherapeutics, Inc. acquiring all common shares of Essa Pharma Inc.
- Shareholders need to be aware of the trading implications during the Due Bill Period.
- The distribution represents more than 25% of the price of common shares, affecting trading dynamics.
Essa Pharma Inc.'s return of capital distribution and trading with due bills reflect significant changes in the company's operations due to the transaction with XenoTherapeutics, Inc. Shareholders should review their trading decisions carefully during the Due Bill Period.